A biomarker test to measure progression for Parkinson's Disease is available in the US before 2029
Salute e medicinaOne-Off2aManifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoPrevisione della comunità attualeSì 71.7%
Previsori
6
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 16 ore fa
Obsoleto25 apr 23, 16:13 UTC2 gen 29, 06:59 UTC
Trend
Regole
There will be a test of a biomarker which meaningfully correlates with parkinson's progression for at least a signficant subset (>10% of those diagnosed clinically) of people with Parkinson's disease in the US before 2029
- examples: Patient has classic non-genetic PD from a clinical diagnosis based on symptoms (rigidity, etc.).
- There will be a test which they can take which shows the severity of the disease, and which when given repeatedly can be used to measure how much or less the disease has progressed
